Concinnity designs unique RNA-based gene control systems that enable the precise control of gene therapies to improve safety.
Total raised: $3.78M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.12.2024 | Seed | $3.78M | - |
Mentions in press and media 4
| Date | Title | Description |
| 17.12.2024 | Concinnity Genetics: Pioneering the Future of Gene Therapy with AI and Innovation | In the heart of Edinburgh, a biotech revolution is brewing. Concinnity Genetics, a startup born from the University of Edinburgh, has secured €3.6 million in seed funding. This financial boost is not just a number; it’s a lifeline for innov... |
| 16.12.2024 | Concinnity secures £3M Seed funding to advance AI-driven gene therapy safety | Edinburgh biotech company Concinnity has raised £3 million Seed funding. Co-founded by Jessica Birt and Dr Matthew Dale, Concinnity is a spinout from the University of Edinburgh that is transforming the safety of gene therapies by designing... |
| 16.12.2024 | Smart genes, smarter funding: Concinnity Genetics raises €3.6 million in funding to develop gene therapy | Edinburgh-based biotech startup Concinnity Genetics has successfully closed an oversubscribed €3.6 million seed funding round. The investment was led by Eos Advisory, with participation from Scottish Enterprise, Old College Capital—the Univ... |
| - | Concinnity Genetics | “Concinnity designs unique RNA-based gene control systems that enable the precise control of gene therapies to improve safety.” |